Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective study of JAK inhibitors in chronic refractory urticaria and urticarial vasculitis
ChiCTR2500098376Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of upadacitinib and tofacitinib in chronic urticaria (CU) and urticarial vasculitis (UV) (2 arms), sponsored by Huashan Hospital. Primary endpoints: UAS7 score, UCT score and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
upadacitinibtofacitinib
03
Conditions
chronic urticaria (CU)urticarial vasculitis (UV)
Beyond the preview
Go deeper on ChiCTR2500098376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098376.